Psoriasis treatment: Current and emerging directed therapies

Annals of the Rheumatic Diseases

Volumn 64, Issue SUPPL. 2, 2005, Pages

  Winterfield, L S ^a   Menter, A ^a,b,e   Gordon, K ^c   Gottlieb, A ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; AZATHIOPRINE; CNTO 1275; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; HYDROXYUREA; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ONERCEPT; PIMECROLIMUS; SALAZOSULFAPYRIDINE; TACROLIMUS; TAZAROTENE; TIOGUANINE; UNCLASSIFIED DRUG;

ALOPECIA; AWARENESS; CHEILITIS; CHILL; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONFERENCE PAPER; DAILY LIFE ACTIVITY; DERMATITIS; DISEASE SEVERITY; DRUG EFFICACY; EPISTAXIS; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPEROSTOSIS; INJECTION SITE REACTION; MYALGIA; NAIL DYSTROPHY; NAUSEA; OPPORTUNISTIC INFECTION; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOTUMOR; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RHINITIS; SIDE EFFECT; SKIN ABRASION; SKIN TOXICITY; SOCIAL INTERACTION; SYSTEMIC THERAPY; TUBERCULOSIS; VISUAL DISORDER; VOMITING; XEROSIS;

ARTHRITIS, PSORIATIC; BIOLOGICAL RESPONSE MODIFIERS; DERMATOLOGIC AGENTS; HUMANS; PSORIASIS; RETINOIDS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 14244262057     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.032276     Document Type: Conference Paper

References (69)

1. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-20.
2. Fleischer AB Jr, Feldman SR, Rapp SR, Reboussin DM, Exum ML, Clark AR, et al. Disease severity measures in a population of psoriasis patients: the symptoms of psoriasis correlate with self-administered psoriasis area severity index scares. J Invest Dermatol 1996;107:26-9.
3. Finlay AY, Kelly SE. Psoriasis-an index of disability. Clin Exp Dermatol 1987;12:8-11.
4. Finlay AY. Quality of life assessments in dermatology. Semin Cutan Med Surg 1998;17:291-6.
5. McKenna KE, Stern RS. The outcomes movement and new measures of the severity of psoriasis. J Am Acad Dermatol 1996;34:534-8.
6. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Quality of life measures in psoriasis: a critical appraisal of their quality. J Clin Pharm Ther 1998;23:391-8.
7. Rapp SR, Exum ML, Reboussin DM, et al. The physical, psychological, and social impact of psoriasis. J Health Psychol 1997;2:525-37.
8. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7.
9. Krueger G, Feldman SR, Camiso C, Duvic M, Elder JT, Gottlieb AB, et al. Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43:281-5.
10. Nickaloff BJ, Kunkel SL, Burdick M, Strieter RM. Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model. Am J Pathol 1995;146:580-8.
11. Boehncke WH, Dressel D, Zollner TM, Kaufmann R. Pulling the trigger on psoriasis. Nature 1996;379:777.
12. Gilhar A, David M, Ullmann Y, Berkutski T, Kalish RS. T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. J Invest Dermatol 1997;109:283-8.
13. Sugai J, Iizuka M, Kawakubo Y, Ozawa A, Ohkido M, Ueyama Y, et al. Histological and immunocytochemical studies of human psoriatic lesions transplanted onto SCID mice. J Dermatol Sci 1998;17:85-92.
14. Yamamoto T, Matsuuchi M, Katayama I, Nishioka K. Repeated subcutaneous injection of stophylococcal enterotoxin B-stimulated lymphocytes retains epidermal thickness of psoriatic skin-graft onto severe combined immunodeficient mice. J Dermatol Sci 1998;17:8-14.
15. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 1979;301:555.
16. Ellis CN, Gorsulowsky DC, Hamilton TA, Billings JK, Brown MD, Headington JT, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986;256:3110-16.
17. Waters CA, Snider CE, Itoh K, Poisson L, Strom TB, Murphy JR, et al. DAB486IL-2 (IL-2 toxin) selectively inactivates high-affinity IL-2 receptor-bearing human peripheral blood mononuclear cells. Ann N Y Acad Sci 1991;636:403-5.
18. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:442-7.
19. Bagel J, Garland WT, Breneman D, Holick M, Liltlejohn TW, Crosby D, et al. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol 1998;38:938-44.
20. Bjerke JR, Krogh HK, Matre R. Characterization of mononuclear cell infiltrates in psoriatic lesions. J Invest Dermatol 1978;71:340-3.
21. Bas JD, Hulsebosch HJ, Krieg SR, Bakker PM, Cormane RH. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983;275:181-9.
22. Kreuger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005;64(suppl II):ii30-6.
23. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 2002;138:657-63.
24. Chisholm PL, Williams CA, Jones WE, Majeau GR, Oleson FB, Burrus-Fischer B, et al. The effects of an immunomodulatory LFAS-IgG1 fusion protein on nonhuman primates. Ther Immunol 1994;1:205-16.
25. Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD, et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993;178:211-22.
26. Meier W, Gill A, Rogge M, Dabora R, Majeau GR, Oleson FB, et al. Immunomodulation by LFA3TIP, and LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Ther Immuno 1995;2:159-71.
27. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 1994;152:2753-67.
28. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE; Alefocept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefocept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-27.
29. Kraan MC, van Kuijk AW, Dinant HJ, Goedkoop AY, Smeets TJ, de Rie MA, et al. Alefocept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002;46:2776-84.
30. Van Seventer GA, Shimizu Y, Horgan KJ, Luce GE, Webb D, Shaw S. Remote T cell co-stimulation via LFA-1/ICAM-1 and CD2/LFA-3: demonstration with immabilized ligand/mAb in monocyte-mediated co-stimulation. Eur J Immunol 1991;21:1711.
31. Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T, et al. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996;157:4986-95.
32. Krueger J, Gottlieb A, Miller B, Dedrick R, Garovoy M, Walicke P. Anti-CD11a a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J Invest Dermatol 2000; 115:333.
33. Chamian F, Lin S, Novitskaya I, et al. Presence of " inflammatory" dendritic cells in psoriasis vulgaris lesions and modulation by efolizumab (anti-CD11a). Poster presented at the 65th annual meeting of the Society for Investigative Dermatology, 29 April-1 May 2004, Providence, RI, USA.
34. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073-80. Erratum in: JAMA 2004;291:1070.
35. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073-80. Erratum in: JAMA 2004;291:1070.
36. Gaylor ML, Duvic M. Generalized pustular psoriasis following withdrawal of efalizumab. J Drugs Dermatol 2004;3:77-9.
37. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994;102:145-9.
38. Ohta Y, Hamada Y, Katsuoka K. Expression of IL-18 in psoriasis. Arch Dermatol Res 2001;293:334-42.
39. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy in patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol (in press).
40. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etonercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-32; discussion 1632.
41. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etonercept Psoriasis Study Group. Etonercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22.
42. Moreland LW, Schiff M, Cohen S, Fleischmann RM, Baumgartner S, Burge D, et al. Safety and efficacy of up to 5 years of etonercept (Enbrel) therapy in rheumatoid arthritis. Presented at the European League Against Rheumatism 12-15 June 2002.
43. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etonercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000;356:385-90.
44. Chen DM, Gordon K, Leonardi MD, et al. Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: Preliminary findings from a 12-week dose-ranging trial. J Am Acad Dermatol 2004;50(3 Pt II), and PS 491; Ps.
45. Menter A. Onercept. Presented at the International Psoriasis Society Meeting, June 2003, New York.
46. Lowe NJ, Lazarus V, Matt L. Systemic retinoid therapy for psoriasis. J Am Acad Dermatol 1988; 19:186-91.
47. Ling MR. Acitretin: optimal dosing strategies. J Am Acad Dermatol 1999;41:S13-S17.
48. Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol 1999;41:S22-S24.
49. Lowe NJ, Prystowsky JH, Bourget T, Edelstein J, Nychay S, Armstrong R. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991;24:591-4.
50. Lebwohl M, Drake L, Menter A, Koo J, Gottlieb AB, Zanolli M, et al. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 2001;45:544-53.
51. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Combination regimens of topical calcipotriene in chronic plaque psoriasis: systematic review of efficacy and tolerability. Arch Dermatol 2000;136:1536-43.
52. Lowe NJ, Lew-Kaya D, Walker PS. Safety of oral tazarotene in nodulocystic acne. Presented at the 62nd annual meeting of the American Academy of Dermatology, 6-11 February 2004, Washington DC, poster no. 67.
53. Walker PS, Gottlieb A, Guenther L, et al. Safety of oral tazarotene in moderate to severe plaque psoriasis. Presented at the 62nd annual meeting of the American Academy of Dermatology, 6-11 February 2004, Washington DC, poster no. 595.
54. Leavell UW Jr, Yarbro JW. Hydroxyurea. A new treatment for psoriasis. Arch Dermatol 1970;102:144-50.
55. Jones EL, Epinette WW, Hackney VC, Menendez L, Frost P. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol 1975;65:537-42.
56. Zackheim HS, Glogau RG, Fisher DA, Maibach HI. 6-Thioguanine treatment of psoriasis: experience in 81 patients. J Am Acad Dermatol 1994;30:452-8.
57. Gupta AK, Grober JS, Hamilton TA, Ellis CN, Siegel MT, Voorhees JJ, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995;22:894-8.
58. Scerri L. Azathioprine in dermatological practice. An overview with special emphasis on its use in non-bullous inflammatory dermatoses. Adv Exp Med Biol 1999;455:343-8.
59. Menter MA, See JA, Amend WJ, Ellis CN, Krueger GG, Lebwohl M, et al. Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994. J Am Acad Dermatol 1996;34:315-21, Erratum in: J Am Acad Dermatol 1996;34:1029.
60. Menter MA, See JA, Amend WJ, Ellis CN, Krueger GG, Lebwohl M, et al. Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994. J Am Acad Dermatol 1996;34:315-21, Erratum in: J Am Acad Dermatol 1996;34:1029.
61. Yamamota T, Nishioka K. Topical tacrolimus: an effective therapy for facial psoriasis. Eur J Dermatol 2003;13:471-3.
62. Mrowietz U, Wustlich S, Hoexter G, Graeber M, Brautigam M, Luger T. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol 2003;83:351-3.
63. Freeman AK, Linowski GJ, Brady C, Lind L, Vanveldhuisen P, Singer G, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003;48:564-8.
64. Duthie MS, Kimber I, Norval M. The effects of ultraviolet radiation on the human immune system. Br J Dermatol 1999;140:995-1009.
65. Tanew A, Guggenbichler A, Honigsmann H, Geiger JM, Fritsch P. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 1991;25:682-4.
66. Iest J, Boer J. Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 1989;120:665-70.
67. Paul BS, Momtaz K, Stern RS, Arndt KA, Parrish JA. Combined methotrexate-ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol 1982;7:758-62.
68. Morison WL, Momtaz K, Parrish JA, Fitzpatrick TB. Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol 1982;6:46-51.
69. Lebwohl M, Ting PT, Koo JYM. Psoriasis treatment: traditional therapy. Ann Rheum Dis 2005;64(suppl II):ii83-6.